29 May , 2026 By : Debdeep Gupta
Lupin share price will remain in focus on May 29 after the pharmaceutical company received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Ankleshwar manufacturing facility in Gujarat.
The EIR was issued following the successful closure of a product-specific pre-approval inspection conducted by the US FDA at the facility from March 2 to March 7, 2026.
Commenting on the development, Nilesh Gupta, Managing Director, Lupin, said this outcome reflected the company's continued focus on quality excellence and regulatory compliance, reinforcing commitment to delivering safe and effective medicines to patients worldwide.
Separately, the company also announced that results from its Phase 1a clinical trial evaluating LNP8701, a novel SOS1 inhibitor, have been accepted for publication at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.
The ASCO 2026 Annual Meeting is scheduled to be held from May 29 to June 2, 2026, in Chicago, Illinois.
Earlier this month, the company received China’s National Medical Products Administration approved for its Abbreviated New Drug Application for Oseltamivir Phosphate, in partnership with Yabao Pharmaceuticals.
In the previous trading session, the share closed at Rs 2,276.75, up Rs 12.90, or 0.57 percent.
The share touched a 52-week high of Rs 2,492.00 and a 52-week low of Rs 1,838.65 on 07 May, 2026 and 06 August, 2025, respectively. Currently, the stock is trading 8.64 percent below its 52-week high and 23.83 percent above its 52-week low.
The market capitalisation of the company stands at Rs 104,096.62 crore.
0 Comment